There are currently 30 clinical trials in Peoria, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including Arizona Center for Cancer Care - Peoria, Pivotal Research Centers, Sun Valley Arthritis Center, Ltd and Pfizer Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
Recruiting
Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH). Researchers want to learn if a study medicine called efinopegdutide can treat MASH.The goals of this study are to learn: * If efinopegdutide can lower the amount of fat, inflammation, and scarring (fibrosis) in the liver * About the safety of efinopegdutide and how well peopl... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/31/2025
Locations: The Institute for Liver Health II dba Arizona Liver Health - Peoria ( Site 0120), Peoria, Arizona
Conditions: Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
Recruiting
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Viking Clinical Site #2018, Peoria, Arizona
Conditions: Weight Loss
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/29/2025
Locations: Akero Clinical Study Site, Peoria, Arizona
Conditions: NASH With Fibrosis, MASH With Fibrosis
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) MASH
Recruiting
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/29/2025
Locations: Arizona Liver Health - Peoria, Peoria, Arizona
Conditions: Metabolic Dysfunction-Associated Steatohepatitis
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Recruiting
This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have metabolic dysfunction-associated steatohepatitis (MASH). MASH is a form of metabolic dysfunction-associated steatotic liver disease (MASLD). MASH occurs when fat builds up in liver cells, damaging them, and making the liver inflamed and stiff from fibrosis (scar tissue). MASH can progress to cirrhosis (long term scarring) and liver failure (when the liver ca... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/29/2025
Locations: The Institute for Liver Health II LLC DBA Arizona Liver Health - Peoria, Peoria, Arizona
Conditions: Metabolic Dysfunction-associated Steatohepatitis (MASH)
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Recruiting
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double... Read More
Gender:
ALL
Ages:
Between 18 years and 63 years
Trial Updated:
07/29/2025
Locations: Arizona Arthritis & Rheumatology Research /ID# 273555, Peoria, Arizona
Conditions: Systemic Lupus Erythematosus
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/28/2025
Locations: Akero Clinical Study Site, Peoria, Arizona
Conditions: NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
Recruiting
The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.
Gender:
ALL
Ages:
Between 50 years and 100 years
Trial Updated:
07/28/2025
Locations: Sun Valley Arthritis Center Ltd, Peoria, Arizona
Conditions: Polymyalgia Rheumatica
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Recruiting
This study is open to adults who are at least 18 years old and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic-associated steatohepatitis (MASH) and * moderate or advanced liver fibrosis People with a history of acute or chronic liver diseases other than MASH or chronic alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with MASH and moderate or advanced liver fibrosi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: The Institute for Liver Health, LLC, Peoria, Arizona
Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Recruiting
This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps peop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: The Institute for Liver Health, LLC, Peoria, Arizona
Conditions: Metabolic Dysfunction Associated Steatohepatitis
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Recruiting
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/25/2025
Locations: Anthos Investigative Site 1099, Peoria, Arizona
Conditions: Atrial Fibrillation (AF)
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
Recruiting
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/23/2025
Locations: Arthrosi Investigative Site (680), Peoria, Arizona
Conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic